CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05722418 · RECRUITING
Trial details
- NCT number
- NCT05722418
- Sponsor
- Caribou Biosciences, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-06
- Primary completion
- 2027-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.